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Abstract
Background: The relative role of anti apoptotic (i.e. Bcl-2) or pro-apoptotic (e.g. Bax) proteins in
tumor progression is still not completely understood.
Methods:  The rat glioma cell line A15A5 was stably transfected with human Bcl-2  and  Bax
transgenes and the viability of theses cell lines was analyzed in vitro and in vivo.
Results: In vitro, the transfected cell lines (huBax A15A5 and huBcl-2 A15A5) exhibited different
sensitivities toward apoptotic stimuli. huBax A15A5 cells were more sensitive and huBcl-2 A15A5
cells more resistant to apoptosis than mock-transfected A15A5 cells (pCMV A15A5). However, in
vivo, in syngenic rat BDIX, these cell lines behaved differently, as no tumor growth was observed
with huBax A15A5 cells while huBcl-2 A15A5 cells formed large tumors. The immune system
appeared to be involved in the rejection of huBax A15A5 cells since i) huBax A15A5 cells were
tumorogenic in nude mice, ii) an accumulation of CD8+ T-lymphocytes was observed at the site of
injection of huBax A15A5 cells and iii) BDIX rats, which had received huBax A15A5 cells developed
an immune protection against pCMV A15A5 and huBcl-2 A15A5 cells.
Conclusions: We show that the expression of Bax and Bcl-2 controls the sensitivity of the cancer
cells toward the immune system. This sensitization is most likely to be due to an increase in
immune induced cell death and/or the amplification of an anti tumour immune response
Background
Glioblastoma Multiforme (GBM) are the most common
and aggressive tumors of the central nervous system
(CNS) [1]. Current treatments (e.g. chemo-and radiother-
apy) have been relatively unsuccessful and no significant
improvement in the prognosis has been recorded over the
last 20 years [1]. Cancer cells are capable of inducing a
specific immune response against the tumor and this
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property has been used in an attempt to design new ther-
apeutic strategies [2,3]. In particular, anti-tumor vaccina-
tion strategies using known tumor-associated antigens or
whole tumor extracts have been developed over the last
few years [2,3]. However, a growing body of evidence has
recently shown that tumors are capable of suppressing
anti-cancer immune responses by the induction of toler-
ance, anergy or by selective killing of immune cells,
thereby preventing their destruction by the immune sys-
tem [4,5]. Dead cells have been also widely used as a
source of tumor antigen but contradictory results have
been reported on their effect on tumor growth [6]. We [7]
and others [8,9] have shown that apoptotic bodies are
capable of inducing a long-lasting and efficient immune
response against tumors whereas others have suggested
that necrotic cells could be anergic and tolerogenic
[10,11]. Thus, the ability of dead cells to generate an
immune response against a tumor could be associated
with the nature of the death inducer used and/or the
modus operandi of cell death (i.e. necrosis vs. apoptosis).
Cytotoxic T lymphocytes (CTLs) and natural killer cells
(NK), the major actors of the immune surveillance, have
the ability to induce cell death by apoptosis mainly
through two mechanisms: the death receptor pathway
(i.e. CD95/Fas/APO-1, TRAIL) or the cytotoxic granules
(i.e. perforin/granzyme pathway) [4,12]. Activation of
death receptors appears to be sufficient to induce the
cytosolic activation of caspases, the main proteolytic
enzymes of apoptosis, in some tumors (class I) while, in
class II tumors, amplification of the death signal occurs
through mitochondrial activation of caspases [13].
Proteins of the BCL-2 family play a major role in the con-
trol of apoptosis both in vitro and in vivo in the latter path-
way [14]. These proteins can be divided into anti-
apoptotic proteins such as Bcl-2 and pro-apoptotic pro-
teins such as Bax [14]. Inhibition of apoptosis through the
overexpression of Bcl-2 promotes oncogenesis as demon-
strated in some follicular B-lymphomas [15] while, on the
other hand, the loss of Bax function has been associated
with tumor progression and a bad prognosis in colon and
gastric tumors having a microsatellite mutator phenotype
[16]. We have recently observed that the expression of a
gain of function variant of Bax can be associated with a
longer survival in GBM patients [17]. Note that the expres-
sion of the anti-apoptotic molecule Bcl-2 and that of the
pro-apoptotic Bax increased in parallel in low grade to
high grade tumors of glial origin, suggesting that Bax and
Bcl-2 could play an antagonistic but essential role in these
tumors [18]. One of the most powerful mechanisms of
control of tumor growth is exercised by the immune sys-
tem. The immune surveillance hypothesis suggests that
potentially dangerous cells could be eliminated through
induction of cell death [3].
Although the CNS is usually considered an immune priv-
ileged site [5], specific cellular immune responses against
tumoral antigens have been achieved in some animal
models [19,20]. In GBM, the absence of Bax protein is
compensated by an increased expression of Bak, another
multidomain pro-apoptotic protein, which also main-
tains the immune-induced cell death [21]. Thus, manipu-
lation of the expression of the BCL-2 family members
could also be involved in the sensitivity of glial tumors to
the immune system.
We have tested this hypothesis by establishing cell lines,
which stably express transgenes encoding either for
human Bax or Bcl-2 in a rat glioma model and analyzed
the effects of these transgenes on the in vitro and in vivo
growth of these cell lines.
Methods
Reagents
Unless specified, all reagents used in this study were from
Sigma (St Quentin-Fallavier, France). Monoclonal anti-
human Bax antibody (clone 4F11) was from Immunotech
(Villepinte, France) and monoclonal anti-human Bcl-2
antibody (M 0887) was from Dako (Trappes, France);
antibodies against rat Bcl-2 or Bax were respectively from
Oncogene (Ab5) (Fontenay sous Bois, France) and from
Pharmingen (13456E) (Le Pont de Claix, France). The
fluorogenic peptide Ac-DEVD-AMC was from Bachem
(Voisins les Bretonneux, France) and the lactate dehydro-
genase (LDH) activity was measured using the Cytotox
96®  assay from Promega (Charbonnières, France) as
described previously [17,18,21].
Experimental research on animals have been conducted
according to recommendations of the French National
Ethics committee, and are in compliance with the Hel-
sinkiDeclaration.
In vitro transfection, proliferation and induction of 
apoptosis
The rat glioma cell line, A15A5, was obtained from the
European Collection of Animal Cell Culture (Valbonne,
France). The cell line was maintained in RPMI-1640 (Inv-
itrogen, Cergy-Pontoise, France) supplemented with 10%
heat-inactivated FCS (Eurobio, Les Ulis, France), 100 µg/
ml streptomycin, 100 U/ml penicillin and 2 mM L-gluta-
mate in a 5% CO2 air-humidified atmosphere at 37°C.
Plasmids encoding for human Bcl-2 or Bax were sub-
cloned into pRcCMV (Invitrogen) as described by the
manufacturer. A15A5 cells were transfected with either 2
µg pCMV vector, pCMV Bcl-2 or pCMV Bax. Plasmid DNA
was introduced into 106  cells by electroporation
(GenePulser, BioRad, Yvry sur Seine, France) using 200 V/
cm and 250 µF. Transfected cells were selected and clonedBMC Cancer 2004, 4:54 http://www.biomedcentral.com/1471-2407/4/54
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in a medium containing neomycin (250 µg/ml) for sev-
eral weeks before clonal dilution.
Apoptosis was induced by a short UV-treatment. Both
untreated and UV-treated cells were cultured for a further
24 h under serum-free conditions. Cell death was also
induced with FasL (0.5 µg/ml; a gift of Dr P. Saas EPI 119,
Besançon, France), doxorubicin (doxo; 2 µM), stau-
rosporine (STS; 1 µM), Na-Butyrate (NaB; 10 mM) or
serum deprivation (d-serum) for 3 days. A MTT assay was
used according to the manufacturer's instructions
(Promega) to determine in vitro cell proliferation of trans-
fected A15A5 cells.
Tumor and cell extracts and Western blots
A15A5 transfected cells (105 cells) or tumors established
in rats or mice were homogenized vol./vol. in RIPA buffer
(PBS containing 1% NP-40, 0.5% Na-deoxycholate, 0.1%
SDS, 10 nM PMSF, 10 nM aprotinin, 1 nM Na-orthovana-
date). After several passages in a 2 ml glass Dounce
homogenizer, the homogenates were centrifuged at 4°C
at 13,000 g for 30 min. The resulting supernatants were
assayed for protein concentration using the Bradford tech-
nique prior to analysis on 15% SDS-PAGE. Western blots
were performed as described earlier [21], using primary
antibodies anti-Bcl-2 (1 µg/ml), anti-Bax (2 µg/ml) and
actin (0.5 µg/ml). The antibodies bound to Immobilon-P
(Millipore, France) were detected by enhanced chemilu-
minescence (Amersham, Aylesbury, UK) using a second
peroxydase-labelled antibody. The amount of immunore-
active protein was quantified using IP-Lab Gel Program
(Signal Analytics, Vienna, USA) after scanning with an
Imager (Q-Biogene, Strasbourg, France).
Animal experiments
Inbred BDIX rats and Swiss nude mice were purchased
from Iffa-Credo (L'Abresle, France) and were housed
under standard conditions in our laboratory. huBax and
huBcl-2 as well as pCMV A15A5 cells were injected into
the brain of BDIX rats weighing between 200 and 240 g.
All animal procedures were performed with approved
protocols and in accordance with published recommen-
dations for the proper use and care of laboratory animals.
Briefly the rats were anaesthetised with an intraperitoneal
injection of pentobarbital (50 mg/kg) and positioned in a
stereotactic head frame. Aseptic surgical techniques were
used to open the scalp in the midline and to expose the
frontal and temporalis bones. A 1.0 mm aperture for
implanting tumor cells was drilled through the skull. The
stereotaxic position of this injection site was 2.5 mm ante-
rior to the bregma and 2.0 mm to the right of midline. 104
tumor cells were implanted stereotactically at a depth of
3.0 mm into the cerebral parenchyma using a 10 µl Ham-
ilton syringe with a 26-gauge needle. The volume injected
was 5 µl and the hole was sealed with sterile bone wax.
Alternatively, rats were injected sc with 105 cells into the
hindlimbs and tumor growth was monitored every week
by measuring the volume of the growing tumors. Swiss
nude mice were treated similarly except that 104 cells were
injected subcutaneously.
In order to evaluate the implication of huBax A15A5 cells
preventive anti-tumoral treatment, we designed a proto-
col consisting of three sc injections of 3.3 × 104 huBax
A15A5 cells 15, 10 and 5 days before injection of pCMV
or huBcl-2 A15A5 cells. As a control PBS, A15A5 cell onc-
olysate, or apoptotic bodies derived from Na-Butyrate
(NaB)-treated A15A5 cells as previously described [7].
Briefly, apoptosis was induced in vitro by a 10 mM NaB
treatment in subconfluent A15A5 cultures. When signs of
apoptosis were observed under a microscope (changes in
cell morphology, detachment from dishes, chromatin
condensation as viewed with Hoechst 33342) apoptotic
bodies were collected, centrifuged and conserved at -80°C
prior to use. Typically, 250 µg apoptotic bodies were
mixed with 5 mg/ml BCG and injected subcutaneously
three times over 15 days. As a control we used oncolysates
obtained after several cycles of rapid freezing/ thawing of
A15A5 cells and the lysates was injected together with 5
mg/ml BCG to the animals as above. On day 0, 5 days
post-treatment, four groups of rats were sc challenged with
105 pCMV or huBcl-2 A15A5 cells. Tumor growth was
evaluated daily over 60 days.
Immunohistochemical analysis of tumor cell injection site
Immunochemical analysis was performed as on 12 µm
brain frozen sections. Briefly, sections were fixed with 4%
paraformaldehyde in PBS for 30 min at room tempera-
ture. Endogenous peroxydase activity was inhibited by a
treatment with 0,3% H2O2 in methanol for 20 min. The
sections were incubated overnight at 4°C with anti-rat
CD8 (hybridoma supernatant, Ox 8) diluted 1 in 2 in 1%
BSA in PBS, then a secondary antibody coupled to perox-
ydase was added. The staining was revealed with an AEC
substrate.
Flow cytometry determination of intratumoral immune 
population
Tumors were resected and minced into 1–2 mm3 pieces,
which were incubated in extraction buffer (30 U/ml
hyaluronidase; 500 U/ml DNase, 0.01% w/v collagenase
in PBS) at room temperature for 45 min and under con-
stant agitation. The cell suspension was filtered through a
sterile grid and washed three times with RPMI and main-
tained overnight in RPMI before analysis. For the pheno-
typic analysis, monoclonal antibodies obtained from
Pharmingen raised against the following molecules were
used: CD3 (556970; cl. 1F4), CD4 (554835, cl ox35),
CD8 (554854, cl. Ox 8), CD161 (555006, cl. 10/78),
CMH I (22301 D), OX 41/ CD172 (552297) and OX 62BMC Cancer 2004, 4:54 http://www.biomedcentral.com/1471-2407/4/54
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(555010). Monoclonal antibodies raised against
granzyme B (GrB, cl. 2C5/F5) was obtained from Chemi-
con (France) and Fas (AF 126) from R&D Systems (Lille,
France). Cells were incubated with the primary antibodies
for 30 min at 4°C and washed twice in PBS + 0.1% BSA.
For the intracellular detection of GrB, cells were first fixed
in 4% paraformaldehyde for 10 min at room temperature,
washed with PBS + 0.1% BSA, then permeabilized with
0.1% saponin then incubated with the anti-GrB antibody
for 30 min. The secondary antibody was then added for 30
min at 4°C and the cells washed 3 times with PBS + 0.1%
BSA. Cells were analyzed on FACScalibur (Becton Dickin-
son, Le Pont de Claix France) using Cell Quest Pro soft-
ware. A total of 5000 cells were counted in each
experiment.
Results
Charaterization of rat glioma cells transfected with human 
Bax or Bcl-2 transgenes
A15A5 cells transfected with the pCMV vector, human Bax
or Bcl-2 transgenes, were obtained as described in materi-
als and methods. Two different clones were used in each
experiment. The expression of the transgenes was moni-
tored by immunoblot analysis using antibodies specific
for human Bcl-2 or Bax and, as shown in figure 1A, trans-
fections of the rat glioma cell line with human transgenes
were efficiently achieved. Note that the overexpression of
Bax did not induce apoptosis in the A15A5 cells, suggest-
ing that the different clones selected expressed sublethal
amounts of Bax.
To examine the effect of the different transgene expression
to cell death, we studied their sensitivity toward different
inducers of apoptosis using both drugs such as doxo (20
ng/ml) and STS (20 µM) or treatments such as d-serum,
NaB (10 mM) or a short (1 min) UV irradiation. Cell
death was monitored and quantified by measuring the
activity of caspase 3 (namely the cleavage of the peptide
Ac-DEVD-AMC) and the activity of the cytosolic enzyme
LDH released into the culture medium (see materials and
methods). As shown in figure 1B, when compared to
pCMV A15A5 cells, huBax A15A5 cells were more sensi-
tive to cell death in all cases. Conversely and as expected,
huBcl-2 A15A5 cells were more resistant to all death
inducers. Note that the resistance of pCMV A15A5 cells to
apoptosis was already high, suggesting that these cells
were naturally resistant to apoptosis. Nevertheless, these
results suggest that human Bax and Bcl-2 transgenes were
functional in the rat glioma A15A5 cells.
The immune system exerts its anti-tumoral surveillance
mainly through cell death induced by CTLs and NK [12].
These cells use different effectors to mediate apoptosis in
target cells: the death receptor mechanism such as the
FasL/Fas receptor system or the perforin/GrB cytotoxic
A. Western blot analyses of human Bcl-2 and Bax transgenes  expression in stable A15A5 transfectants Figure 1
A. Western blot analyses of human Bcl-2 and Bax transgenes 
expression in stable A15A5 transfectants. Two clones per 
transfection with pCMV (E12 and C4), pCMV-Bcl-2 (Bcl-2: 
D6 and D4), pCMV-Bax (Bax: H11 and E4), which expressed 
approximately the same amount of trangenes were selected 
to be used in this study. B. The effect of huBcl-2 and huBax 
on the sensitivity of A15A5 cells to apoptosis, transfected 
cells was analysed after incubated with various cell death 
inducers as described in materials and methods. Apoptosis 
was determined by measuring the specific DEVDase and 
LDH activities after treatment of the cells with doxorubicin 
(doxo), staurosporine (STS), Na-Butyrate (NaB), serum dep-
rivation (d-serum) or UV irradiation (UV). S.D. was calcu-
lated from 3 different experiments using 2 independent 
clones for each transgene. C. Cell death was induced by FasL 
and GrB. A15A5 cells were treated with FasL (0.5 µg/ml) or 
were transfected with a plasmid encoding for human GrB 
(200 µg plasmid) as described in 21. In the latter case, we 
verified by FACS that similar amounts of human GrB were 
expressed in all transfected clones (data not shown). S.D. 
was calculated from 3 different experiments using 2 inde-
pendent clones for each transgene.
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pathway [12]. The ligation of the death ligands to their
receptors initiates cell death by the activation of the
intracellular initiator caspase 8, which in turn can induce
apoptosis either through the direct activation of caspase 3
in type I cells or by using mitochondria as an obligatory
amplifier of the death signal in type II cells [4]. Cytolytic
granules function through the serine protease GrB, which
activates apoptosis mainly through the mitochondrial
pathway [12]. We investigated the in vitro response to
externally added FasL or by transient transfection of
pCMV GrB, huBax A15A5 and huBcl-2 A15A5 cells as
described previously for human glioma cells [21]. As
shown in figure 1C, the expression of Bax sensitized the
A15A5 cells to apoptosis induced by both FasL and GrB
while apoptosis was inhibited by the presence of Bcl-2
under the same conditions. Incidentally, the fact that
huBax or huBcl-2 transfection modulated apoptotic sensi-
tivity toward FasL suggests that the A15A5 cells belong to
the type II group.
Bcl-2 expression has been associated with retardation in
cell cycle entry [22] and as such we examined the prolifer-
ation rate of the different transfected cells using a MTT
assay as described in material and methods. All trans-
fected cells appeared to have a similar doubling time,
which means that the expression of human Bax or Bcl-2
transgenes did not affect their proliferative capacity in vitro
(figure 2A). Similarly, no significant differences in the
effect of the transfection of pCMV, huBcl-2 or huBax
A15A5 in A15A5 cells on the clonogenicity of the glioma
cells were observed as shown in figure 2B.
Tumorigenicity of Bax and Bcl-2 transfected cells
To determine the influence of Bax and Bcl-2 on tumoral
growth in vivo, 104 pCMV, huBcl-2 or huBax A15A5 cells
were delivered intracranially (ic) into syngenic BDIX rats
as described in materials and methods. The survival rates
of the different groups of rats were different as the median
survival for the group of rats which had received huBcl-2
A15A5 and pCMV A15A5 cells were respectively 10.2 and
15.6 days, a difference, which was highly significant (P =
0.0086) (figure 3A). On the other hand, 80% of rats,
which were injected with huBax A15A5 cells, had a dis-
ease-free survival of at least 30 days (figure 3A). It should
be noted that 20% of the death, which occurred after
injection of huBax, huBcl-2 or pCMV-A15A5 cells
appeared to be due to operation-induced traumatisms
since sham-operated animals gave similar results (data
not shown). Brain sections from rats injected with huBcl-
2 or A15A5 cells were histologically examined at the time
of their death or after 30 days for rats injected with huBax
A15A5 cells. As illustrated in figure 3B, brain sections
from rats injected with huBax A15A5 cells showed little or
no tumoral growth contrary to that observed in rats
injected with pCMV or huBcl-2 A15A5 cells. This result
suggested that tumoral growth was severely impaired in
huBax A15A5 tumors but stimulated in huBcl-2 A15A5
tumors when compared to pCMV A15A5 tumors.
To gain information about the kinetics of tumoral growth,
cells were subcutaneously (s.c.) injected into the hind-
limbs of syngenic BDIX rats and the volume of the tumors
evaluated every 10 days. As shown in figure 3C, results
similar to that obtained with i.c. experiments were
observed as no or little growth was observed with huBax
A15A5 tumors whereas huBcl-2 A15A5 tumors exhibited
a faster growth than pCMV A15A5 tumors.
To test the involvement of the innate immunity in the
control of proliferation, the different types of transfected
cells (105) were inoculated s.c. into Swiss nude mice (see
materials and methods). Tumor growth in the mice was
measured for a period of 45 days (figure 4), tumors devel-
oped rapidly with similar kinetics for all the A15A5 trans-
A. In vitro proliferation of transfected A15A5 cells was deter- mined using a MTT assay Figure 2
A. In vitro proliferation of transfected A15A5 cells was deter-
mined using a MTT assay. S.D. were calculated from 3 differ-
ent experiments using for each, one of the 2 different clones 
for pCMV, Bcl-2 or Bax transfected cell lines. B. For the clo-
nogenicity assay: 400 cells were plated into 6-well plates and 
colonies formed were counted as described in 21. Data were 
given as number of CFU (colony forming units) with S.D. cal-
culated from 3 independent clones for each transgene.
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fected cells including huBax A15A5 cells. Immunoblot
analysis of Bax and Bcl-2 in tumors did not reveal any
changes in the expression of Bcl-2 between the established
tumors and the huBcl-2 A15A5 cells (data not shown).
This result showed that the growth of the huBax A15A5
was not due to the induction of rat Bcl-2 expression dur-
ing tumoral growth in the Swiss nude mice.
Accumulation of CD8+ T cells in huBax A15A5 tumors
The latter result suggested that immune-induced apopto-
sis could be involved in the control of tumoral
progression of A15A5 cells in BDIX rats, a feature partially
lost in athymic mice. To assess local anti-tumoral
response, we first investigated the presence of the CD8
marker in the different rat brain sections (figure 3B). The
immunochemical analysis revealed a significant number
of infiltrating CD8+ cells in huBax A15A5 tumors whereas
huBcl-2 A15A5 or pCMV tumors showed very few CD8+
cells (figure 5A). Moreover, we noticed that necrotic tissue
was absent, thus excluding a non-specific recruitment of
lymphocytes due to an inflammatory process.
Next, we also quantified the accumulation of CD8+ cells
by flow cytometry and examined the phenotypes of the
infiltrating immune cells in ic tumors for the presence of
intra-tumoral lymphocytes, monocytes and dendritic cells
or the loss of the major histocompatibility (MHC) class I
molecules. Tumoral cells were dissociated and enzymati-
cally treated as described in materials and methods. We
observed a significant increase in double positive cells
CD3/CD8 in huBax A15A5 tumors (~17%) compared to
huBcl-2 (~4%) and pCMV (~6%) tumors (figure 5B). An
in-depth analysis of these CD3/CD8 cells (figure 5C)
showed that only the lymphocyte T markers and the NK
marker CD161 were significantly increased in huBax
A15A5 tumors. On the other hand, no differences were
found in the expression of class I MHC among the differ-
ent tumors. The latter result suggested that T-cell mediated
immunity could be involved in the rejection of the huBax
A15A5 cells in syngenic rats. However, NK cells could play
A. Growth of pCMV, Bcl-2 and Bax clones in BDIX syngenic  rats Figure 3
A. Growth of pCMV, Bcl-2 and Bax clones in BDIX syngenic 
rats. 105 cells from each clone were injected ic and rat sur-
vival was quantified using a Kaplan-Meier analysis. The curve 
illustrated is representative of 3 independent experiments. 
Each point represents the mean growth of 6 rats (3 rats per 
clone). B. The macroscopic observation of the tumors 
induced by the ic injection of huBcl-2, pCMV and huBax 
A15A5 cells into rat brains. Rat brains were stained with 
hematoxylin. C. Subcutaneous growth was followed by 
measuring the tumoral volume every 10 days after the injec-
tion of the cells. The curve illustrated is representative of 3 
independent experiments. Each point represents the mean 
growth of 6 rats (3 rats per clone).
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an auxiliary role in this process as suggested by the results
obtained in nude mice.
huBax A15A5 cells and A15A5 apoptotic bodies confer a 
protection against pCMV A15A5 cells and to a lesser 
extent against huBcl-2 A15A5 cells
The A15A5 rat glioma cells are highly immunogenic in the
syngenic host [23], this immune response could eradicate
tumors prone to apoptosis such as huBax A15A5 cells
without affecting the viability of the cells resistant to
apoptosis such as the pCMV or the huBcl-2 A15A5 cells.
We have previously shown that apoptotic bodies derived
from cells obtained from a rat colon carcinoma were a
source of anti-tumoral antigens [7,24]. It is conceivable
that the enhanced rate of cell death observed in huBax
A15A5 tumors in vivo could generate a stronger immune
response to pCMV or huBcl-2 A15A5 tumors.
A. Qualitative analysis of CD8+ infiltrating lymphocytes by  immunohistochemistry Figure 5
A. Qualitative analysis of CD8+ infiltrating lymphocytes by 
immunohistochemistry. B. Flow cytometric analyses of intra-
tumoral CD8+ CTLs. Dot plots show the expression of 
CD3+ and CD8+ cells in the dissociated tumors. The per-
centages indicate the double positive cells for the three types 
of tumors. Results are representative of three independent 
experiments. C. Phenotypes of the intra-tumoral cells by 
flow cytometry. Tumors were treated as described in mate-
rials and methods. Results presented here are the mean of 3 
independent experiments.
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pCMVA15A5   huBcl-2 A15A5 huBax A15A5
OX18 (MFI) 280.03 r 85.5 323.6  r 59.85 253.3 r 41.5
CD3/CD4 (%) 0.16 r 0.07 0.08 r 0.05 0.48 r 0.01
CD3/CD8 (%) 6.15 r 0.55 3.80 r 0.38 18.37 r 0.80
CD161 (%) 7.30 r 0.78 2.50 r 0.72 15.03 r 0.55
OX62 (%) 8.53 r 1.98 5.33 r 2.08 10.13 r 2.66
OX41 (%) 8.20 r 1.80      3.60 r 1.37     10.10 r 3.17
CD3/Fas-L (%) 5.03 r 0.89 2.58 r 0.50 9.30 r 1.21
CD3/Gr-B (%) 3.43 r 0.45 1.16 r 0.45 5.67 r 0.76
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A. Vaccination protocol for the anti-tumoral immune 
response induced by huBax A15A5 cells, apoptotic bodies or 
oncolysates to pCMV or huBcl-2 A15A5 cells in rats. Rats 
were pretreated with PBS, oncolysate (OL) or apoptotic 
bodies (AB) from pCMV A15A5 cells or huBax A15A5 cells, 
15, 10 and 5 days before being challenged with pCMV or 
huBcl-2 A15A5 cells. B. Comparison of tumor growth of 
pCMV A15A5 cells injected into syngenic BDIX rats. Four 
groups of 6 BDIX rats were treated as in A then on day 0 
were challenged with 105 pCMV A15A5 cells injected sc and 
tumoral growth was followed for an 60 days. Data presented 
are illustrative of 3 independent experiments. C. Compari-
son of tumor growth of huBcl-2 A15A5 cells injected into 
syngenic BDIX rats. Four groups of 6 BDIX rats were treated 
as in A then on day 0 were challenged with 105 huBcl-2 
A15A5 cells injected sc and tumoral growth was followed for 
an 60 days. Data presented are illustrative of 3 independent 
experiments.
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To address this question, we compared the efficacy of an
anti-tumoral immune response induced by huBax A15A5
cells to that observed with apoptotic bodies or oncolysates
obtained from A15A5 cells (see protocol in figure 6A).
Apoptotic bodies were generated from A15A5 cells treated
with 10 mM NaB as described earlier [7] and their molec-
ular characterization will be published elsewhere
(Bougras et al. in preparation). BDIX rats were vaccinated
with these apoptotic bodies using as a control A15A5 cell
oncolysates or PBS (cf. materials and methods). The rats
were then challenged either with pCMV A15A5 cells
(figure 6B) or huBcl-2 A15A5 cells (figure 6C). As shown
in figure 6B, the tumoral growth of pCMV A15A5 cells was
reduced after the apoptotic body treatment although the
effect was limited in amplitude and in time. On the other
hand, no effect on tumor growth was observed after a sim-
ilar treatment with A15A5 oncolysates (compared figure
6B with figure 3A). Interestingly, the treatment with apop-
totic bodies triggered a weaker response to huBcl-2 A15A5
cells, which grew rapidly in animals treated with apop-
totic bodies or oncolysate (figure 6C). As shown in figure
6B, rats that had received huBax A15A5 cells, then chal-
lenged with pCMV A15A5 cells developed small palpable
tumors, which did not progress after 35 days post-chal-
lenging (i.e. pCMV A15A5 cell proliferation was abolished
after 35 days by a huBax A15A5 cell pretreatment). Note
that huBcl-2 A15A5 cell proliferation was reduced but not
abolished in these rats (figure 6C). These results suggested
that rats that had received huBax A15A5 cells were specif-
ically protected against tumor growth and that the overex-
pression of Bcl-2 could not completely overcome this
protection.
Discussion
Tumor recurrence after surgical resection is often observed
in GBM patients and additional chemo-or radiotherapy
has not been shown to substantially improve survival in
these patients [1]. In animal models, cancer vaccines have
been shown to procure an appropriate immune response,
to be highly specific and to favor tumor rejection [25]. In
the case of CNS tumors, intensive research has been per-
formed in the field of immunotherapy since the discovery
that the CNS could not be regarded any longer as a com-
pletely immunologically privileged site [25]. Phase I stud-
ies have demonstrated the feasibility and the safety of this
approach in human gliomas (see for example [26]). How-
ever, although some promising results have been
obtained in preclinical studies, so far most clinical
attempts have been disappointing. This setback in the
application of immunotherapy is, however, not restricted
to CNS tumors and new strategies are now being elabo-
rated to enhance the efficiency of this approach. Others
and we have observed that apoptotic bodies, the entities
derived from apoptotic cells, could be a source of « new »
anti-tumoral antigens and as such could be a source of
potent tumor vaccines [7-9]. However, the nature of the
cell death program, which gives an appropriate anti-
tumoral immune response remains controversial [6].
Apoptosis is thought to be critical for the development
and the progression of cancer and it appears to be
involved in numerous steps in tumor progression [27].
Impairment or dysregulation of apoptosis clearly provides
a selective advantage to tumoral cells. This resistance
could allow the neoplastic cells to evade immunosurveil-
lance as well as environmental changes inherent to
tumoral transformation. Indeed, this could explain why,
at diagnosis, most tumors have already acquired a certain
resistance to apoptosis [28]. This positive selection for
apoptosis-resistant tumor cells is accentuated by current
therapies (chemo-and radio-therapies), which also use
the apoptotic program to kill cancer cells, and thus tumors
resistant to these treatments are often highly resistant to
apoptosis [29]. Thus, all therapeutic approaches should
take into account this innate or acquired resistance in the
design of new anti-cancer strategies.
We have addressed the question of the role of apoptosis in
tumor progression by using human Bax or Bcl-2 trans-
fected cells and then analyzing tumoral growth in rats.
Several clones of the rat glioma A15A5 cells stably trans-
fected with human Bcl-2 or Bax were used (figure 1A). In
vitro experiments suggest that the expression of the tran-
genes confer the expected different sensitivities toward
apoptosis (figure 1B). We also show that neither the in
vitro  proliferation nor clonogenicity of these cells was
affected by the expression of Bcl-2 or Bax (figure 2). Quite
remarkably, the expression of Bax suppresses the growth
of these tumors in syngenic rats while that of Bcl-2 seems
to stimulate the growth (figure 3). The control of tumor
growth appeared to be under the control of a specific
immune response against tumors. i)Since all tumors pro-
liferated at the same rate in nude mice (figure 4). ii) In the
rejected tumors (figure 5), a specific increase in CD8+
cytotoxic lymphocytes, which have the potential to recog-
nize and attack the major histocompatibility complex
(MHC) class I-expressing brain cells including tumoral
cells [30,31] were detected. iii) Syngenic rats that have
received huBax A15A5 cells develop an anti-tumoral reac-
tion against A15A5 cells (figure 6). However, this
response was partially occluded by the presence of Bcl-2,
a result consistent with the fact that its expression ren-
dered the cells more resistant to apoptosis including that
induced by the immune system (figure 1C). However, the
accumulation of CD8+ CTL at the site of injection of
huBax A15A5 cells could also suggest that induction of
cell death in tumors facilitated or triggered a greater spe-
cific response. This could explain why an immune
response to tumors was specifically observed in animals
treated with huBax A15A5 cells (figure 6). On the otherBMC Cancer 2004, 4:54 http://www.biomedcentral.com/1471-2407/4/54
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hand, the transfection with huBax could modify the phe-
notype of the rat cells as suggested by previous results
[32]. However, MicroArray analysis of huBax A15A5 ver-
sus huBcl-2 A15A5 cells did not reveal any changes in the
transcriptome of the cells (Cartron and Jézéquel, unpub-
lished observation). Of note, in human glioblastomas
expressing Bax ψ, a highly apoptogenic variant of Bax α
[17], we observed an accumulation of intra tumoral CD8+
cells when compared to Bax α tumors (Bougras et al.,
unpublished results).
The apoptosis index has been found to be of significant
prognostic significance in patients with high-grade astro-
cytomas [33]. Our study provides three new findings,
which should be considered in immunotherapy: i) the
expression of pro-or anti-apoptotic molecules can control
the response of the tumor to the immune system during
the course of tumor progression (at least in class II). Thus,
we suggest that the over-expression of Bcl-2, which often
occurs during tumorigenesis could account for the escape
from the immune surveillance. ii) Anti-apoptotic mecha-
nisms that often impede the success of treatments could
also be an obstacle to immunotherapy. In addition other
anti-apoptotic processes such as the existence of soluble
decoy receptor that impairs FasL induced-apoptosis in
malignant gliomas [34] or the existence of an inactive
granzyme [35] could also be involved in the resistance to
the immune system. iii) The type of cell death (e.g. apop-
tosis vs. necrosis) that induces the best stimulation of the
immune system is still a matter of controversy but our
results suggest that cells sensitized to apoptosis are capa-
ble of providing a long lasting and efficient protection
against tumoral growth.
Interestingly, a rat model of colon carcinoma has been
described in which some clones gave rise to tumors that
constantly expanded in the animal to eventually formed
metastasis (Pro) while others progress for several days
before complete regression (Reg) [36]. The disappearance
of the latter clone has been shown to be controlled and to
be triggered by the immune system and the transfection of
Reg cells by Bcl-2 has been shown to prevent apoptosis
and to restore its tumorigenicity [36]. However, the effect
of the ectopic expression of Bax in the progressive coun-
terpart cell line Pro was not investigated in this work [36].
Our results show thus for the first time, in the same type
of cells, the adverse effects of Bax and Bcl-2 in the antitu-
moral role of the immune system.
Conclusion
Taken together, our data provide evidence that BCL-2
family members control tumor growth through their sen-
sitivity to immune-induced cell death and enhancement
of the immunogenicity of tumor cells.
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